Obesity-associated NLRC4 inflammasome activation drives breast cancer progression
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Obesity is associated with an increased risk of developing breast cancer and is also associated with worse clinical prognosis. The mechanistic link between obesity and breast cancer progression remains unclear, and there has been no development of specific treatments to improve the outcome of obese cancer patients. Here we show that obesity-associated NLRC4 inflammasome activation/ interleukin (IL)-1 signalling promotes breast cancer progression. The tumour microenvironment in the context of obesity induces an increase in tumour-infiltrating myeloid cells with an activated NLRC4 inflammasome that in turn activates IL-1β, which drives disease progression through adipocyte-mediated vascular endothelial growth factor A (VEGFA) expression and angiogenesis. Further studies show that treatment of mice with metformin inhibits obesity-associated tumour progression associated with a marked decrease in angiogenesis. This report provides a causal mechanism by which obesity promotes breast cancer progression and lays out a foundation to block NLRC4 inflammasome activation or IL-1β signalling transduction that may be useful for the treatment of obese cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In those cases, IL-1β is the key player, acting as pro-inflammatory, tumor-promoting trigger [126,127,128,129,130].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [129]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zaafar, D. K., Zaitone, S. A., & Moustafa, Y. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100562 · Cited by 74 · cited 1×
“This is consistent with previous studies that have shown that metformin lowers serum VEGFA levels in both human and mouse 39,40 .”
RetractedObesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041 · cited 1×
“Whether obesity has an impact on these diseases through enhancement of inflammation or via a direct mechanism is largely unclear; however, obese adipose tissue is a reservoir for macrophages with activated inflammasomes that contribute to insulin resistance and diabetes 10,11 .”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“Metformin is known to have pleiotropic effects, and is thought to primarily work by inhibiting mitochondrial respiratory-chain complex-I, which leads to activation of adenosine monophosphate-activated protein kinase 38 .”
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · cited 1×
“We We did observe a significant increase in the number of tumour-infiltrating macrophages (F4/80 þ CD11b þ ); in particular, there was a significant increase in CD11c (cid:2) macrophages and a trend for increased CD11c þ macrophages 21 (Fig.”
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169 · cited 2×
“In addition, KMPlot (http://kmplot.com/analysis/) was used to analyse microarray data sets that were normalized and combined for survival analysis 41 .”
Kim, H. J., Park, S. Y., Choi, Y. J., Han, S. J., Lee, K. W., & Kim, D. J. (2013) · Hormone Research in Paediatrics · doi:10.1159/000348848 · Cited by 3,048
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Metformin, a type 2 diabetes drug, reduces the risk of several types of cancer including breast cancer 35–37 .”
NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis
Elinav, E., Strowig, T., Kau, A. L., Henao-Mejia, J., Thaiss, C. A., Booth, C. J., Peaper, D. R., Bertin, J., Eisenbarth, S. C., Gordon, J. I., et al. (2011) · Cell · doi:10.1016/j.cell.2011.04.022 · Cited by 2,024
Cited by
Items 101–200 of 247
Statin Use, Cholesterol Level, and Mortality Among Females With Breast Cancer
Murto, M. O., Simolin, N., Arponen, O., Siltari, A., Artama, M., Visvanathan, K., Jukkola‐Vuorinen, A., & Murtola, T. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.43861 · Cited by 39
IL-22 Signaling in the Tumor Microenvironment
Jiang, R., & Sun, B. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-55617-4_5 · Cited by 35
Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling
Luca, R. D., Arrè, V., Nardone, S., Incerpi, S., Giannelli, G., Trivedi, P., Anastasiadou, E., & Negro, R. (2025) · Gut · doi:10.1136/gutjnl-2025-334938 · Cited by 37
“45 68 Acute and chronic inflammation, a status often linked with dysbiosis, leads to the release of ASC-dependent mature IL-18, which inhibits the caspase- 8-mediated apoptosis pathway while enhancing the survival and proliferation of GC cells.”
Raut, P. K., & Park, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114186 · Cited by 34
Immuno-metabolic diseases and therapeutics: molecular mechanisms via inflammasome signaling
Han, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02368-9 · Cited by 36
“The relationship between obesity and breast cancer incidence has been explored, revealing a correlation between breast cancer and NLRC4 inflammasome activation in mouse models [106].”
Torres, A. C. M. B. G., Leite, N., Tureck, L. V., de Souza, R. L. R., Titski, A. C. K., Milano, G. E., Lazarotto, L., da Silva, L. R., & Alle, L. F. (2018) · Gene · doi:10.1016/j.gene.2018.11.065 · Cited by 33
Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Chew, V., Chuang, C.-H., & Hsu, C. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01011-y · Cited by 32
Inflammasomes in cancer: Effect of epigenetic and autophagic modulations
Mishra, S. R., Mahapatra, K. K., Behera, B. P., Bhol, C. S., Praharaj, P. P., Panigrahi, D. P., Patra, S., Singh, A., Patil, S., Dhiman, R., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.013 · Cited by 31
Exploiting the obesity-associated immune microenvironment for cancer therapeutics
Desharnais, L., Walsh, L. A., & Quail, D. F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107923 · Cited by 31
Liu, F., Li, L., Lan, M., Zou, T., Kong, Z., Cai, T., Wu, X. Y., & Cai, Y. (2021) · Mediators of Inflammation · doi:10.1155/2021/7785890 · Cited by 33
“Anti-IL-1R1 antibody and anakinra treatment inhibits the growth of E0771 tumor in DIO mice [88].”
InfluentialPrivitera, G., Rana, N., Scaldaferri, F., Armuzzi, A., & Pizarro, T. T. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.806680 · Cited by 32
Dual roles of inflammatory programmed cell death in cancer: insights into pyroptosis and necroptosis
Wang, S., He, H., Qu, L., Shen, Q., & Dai, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1446486 · Cited by 38
Insights into inflammasome and its research advances in cancer
Cao, X., & Xu, J. (2019) · Tumori Journal · doi:10.1177/0300891619868007 · Cited by 33
Li, Y., Yu, W., Xiong, H., & Yuan, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-15607-7 · Cited by 30
Self-citationInnate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy
Lebegge, E., Arnouk, S. M., Bardet, P. M. R., Kiss, M., Raes, G., & Ginderachter, J. A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01395 · Cited by 30
“The role of inflammasome activation in tumor progression is also demonstrated in obese mice, where obesity-associated NLRC4 inflammasome activation in tumor-infiltrating myeloid cells promotes breast cancer progression (33).”
BackgroundNLRC4, inflammation and colorectal cancer (Review)
Tong, G., Shen, Y., Li, H., Qian, H., & Tan, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5687 · Cited by 28
Sestrin2 in cancer: a foe or a friend?
Ala, M. (2022) · Biomarker Research · doi:10.1186/s40364-022-00380-6 · Cited by 28
Liu, J., Liu, Q., Shen, H., Liu, Y., Wang, Y., Wang, G., & Du, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.838624 · Cited by 27
Self-citationTargeting inflammasomes as an immunotherapeutic strategy for cancer
Huang, L., Chen, X., Liu, R., Nan, D., Bao, W., Yang, L., Dai, X., Tang, J., Zhang, H., & Lu, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06665-2 · Cited by 28
“Obesity-related NLRC4 inflammasome activation and IL-1 signaling promote the progression of breast cancer by inducing infiltrative myeloid cells, activating IL-1β, and facilitating disease development via adipocyte-medi-ated VEGFA production and angiogenesis [85].”
Plascak, J. J., Rundle, A., Xu, X., Mooney, S. J., Schootman, M., Lü, B., Roy, J., Stroup, A. M., & Llanos, A. A. M. (2021) · Cancer · doi:10.1002/cncr.33900 · Cited by 26
“Cytokine products of the NOD- like receptor protein (NLRP) inflammasome pathway characterized from the tumor microenvironment have been associated with breast tumor progression.(35) A study of neighborhood factors and peripheral blood DNA methylation among participants in a cardiovascular disease cohort found that a w…”
BackgroundThe role of pyroptosis and its crosstalk with immune therapy in breast cancer
Wu, L., Lu, H., Pan, Y., Liu, C., Wang, J., Chen, B., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973935 · Cited by 31
Crosstalk between hypoxia-induced pyroptosis and immune escape in cancer: From mechanisms to therapy
Meybodi, S. M., Ejlalidiz, M., Manshadi, M. R., Raeisi, M., Zarin, M., Kalhor, Z., Saberiyan, M., & Hamblin, M. R. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104340 · Cited by 27
Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment
Zhang, F., Jiang, J., & Zheng, X. W. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122276 · Cited by 25
Yang, Z., Zeng, H., Li, J., Zeng, N., Zhang, Q., Hou, K., Li, J., Yu, J., & Wu, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35200 · Cited by 28
“Obesity-associated NLRC4 inflammasome induced IL-1 β activation in tumor-associated macrophages (TAMs), which then elevated VEGF-A expression of primary adipocytes and promoted breast cancer angiogenesis and growth [68].”
BackgroundObesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation
Engin, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_26 · Cited by 32
Listeria monocytogenes Cancer Vaccines: Bridging Innate and Adaptive Immunity
Morrow, Z. T., Powers, Z. M., & Sauer, J. (2019) · Current Clinical Microbiology Reports · doi:10.1007/s40588-019-00133-4 · Cited by 25
The Adipocyte–Macrophage Relationship in Cancer: A Potential Target for Antioxidant Therapy
Sanhueza, S., Simón, L., Cifuentes, M., & Quest, A. F. G. (2023) · Antioxidants · doi:10.3390/antiox12010126 · Cited by 24
“Consequently, adipocyte-derived ANGPTL4 promotes obesitydriven breast cancer progression and angiogenesis [39,40].”
BackgroundInfluentialNew prospects of cancer therapy based on pyroptosis and pyroptosis inducers
Chen, Q., Sun, Y., Wang, S., & Xu, J. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01906-5 · Cited by 25
Farag, K., Makkouk, A., & Norian, L. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668494 · Cited by 24
Inflammasomes: Cause or consequence of obesity‐associated comorbidities in humans
Herrera-Martínez, A. D., Herrero‐Aguayo, V., Pérez‐Gómez, J. M., Gahete, M. D., & Luque, R. M. (2022) · Obesity · doi:10.1002/oby.23581 · Cited by 23
“treatment of patients with obesity and cancer [92], but currently, there are no studies in humans that evaluate the effect of inflammasome modulation in tumors.”
BackgroundExploring the role of the inflammasomes on prostate cancer: Interplay with obesity
Pérez‐Gómez, J. M., Montero‐Hidalgo, A. J., Fuentes-Fayos, A. C., Sarmento‐Cabral, A., Guzmán‐Ruiz, R., Malagón, M. M., Herrera-Martínez, A. D., Gahete, M. D., & Luque, R. M. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09838-w · Cited by 24
“Moreover, it has also been reported that obesity-induced NLRC4 inflammasome in tumor-infiltrating myeloid cells promotes angiogenesis in diet-induced obese mice through IL-1β, and that such activation would finally lead to increased Vegfa expression in surrounding adipocytes [184].”
BackgroundTissue factor as a mediator of coagulation and signaling in cancer and chronic inflammation
Graf, C., & Ruf, W. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.023 · Cited by 22
Regulation of Obesity by Antiangiogenic Herbal Medicines
Shin, S. S., & Yoon, M. (2020) · Molecules · doi:10.3390/molecules25194549 · Cited by 23
“For example, activated macrophages produce potent proangiogenic factors, such as TNFα, VEGF, FGF-2, IL-1β, IL-6, and IL-8 [52].”
BackgroundCancer du sein, obésité et tissu adipeux: Un trio à haut risque
Fallone, F., Deudon, R., Muller, C., & Vaysse, C. (2018) · médecine/sciences · doi:10.1051/medsci/2018298 · Cited by 29
Li, J., Chen, Q., Li, S., Zeng, X., Qin, J., Li, X., Chen, Z., Zheng, W., Zhao, Y., Huang, Z., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.145212 · Cited by 24
Hou, J., Li, T., Hsu, J.-M., Zhang, X., & Hung, M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101833 · Cited by 21
Ahmed, H. S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04156-x · Cited by 22
“Obesity induces an increase in tumor-infiltrating MDSCs with activated NLRC4 inflammasome, resulting in IL-1β production, driving tumor progression through adipocyte-mediated VEGF-A expression and angiogenesis [77].”
Manipulation of Inflammasome: A Promising Approach Towards Immunotherapy of Lung Cancer
Sarkar, R. D., Sinha, S., & Biswas, N. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1876044 · Cited by 21
“NLRC4 inflammasome over-activation positively regulates breast cancer progression [67].”
BackgroundLocal Biomarkers Involved in the Interplay between Obesity and Breast Cancer
Holm, J. B., Rosendahl, A. H., & Borgquist, S. (2021) · Cancers · doi:10.3390/cancers13246286 · Cited by 24
Body fatness and mTOR pathway activation of breast cancer in the Women’s Circle of Health Study
Cheng, T. D., Omilian, A. R., Yao, S., Sanchez, P. V., Polk, L. Z., Zhang, W., Datta, S., Bshara, W., Ondracek, R. P., Davis, W., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00187-4 · Cited by 21
Self-citationRegulated lytic cell death in breast cancer
Liu, M., Wang, L., Xia, X., Wu, Y., Zhu, C., Duan, M., Wei, X., Hu, J., & Lei, L. (2021) · Cell Biology International · doi:10.1002/cbin.11705 · Cited by 21
“Kolb et al. (2016) found activation of the NLRC4 inflammasome and activation of IL‐1β in obese BC mice.”
BackgroundGuey, B., Bodnar‐Wachtel, M., Drouillard, A., Eberhardt, A., Pratviel, M., Goutagny, N., Bendriss‐Vermare, N., Puisieux, I., Caux, C., Walzer, T., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01683 · Cited by 20
Jimenez‐Duran, G., & Triantafilou, M. (2021) · Immunology · doi:10.1111/imm.13326 · Cited by 19
“Activated NLRC4 leading to IL-1β signalling has been re-ported to contribute to pathology and angiogenesis in obese mice with breast cancer via adipocyte-mediated vascular endothelial growth factor A (VEGFA) expression [17].”
Body mass index-associated molecular characteristics involved in tumor immune and metabolic pathways
Hu, C., Chen, X., Yao, C., Liu, Y., Xu, H., Zhou, G., Xia, H., & Xia, J. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00225-6 · Cited by 18
Self-citationDomblides, C., Crampton, S., Liu, H., Bartleson, J. M., Nguyen, A., Champagne, C., Landy, E., Spiker, L., Proffitt, C., Bhattarai, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci166085 · Cited by 18
“Notably, a protumorigenic role of NLRC4 coming from the myeloid compartment has been described in mouse models of high-fat diet– induced CRC and breast cancer (27, 28), although the tumor-in-trinsic role of NLRC4 was not investigated.”
Mild-photothermal and nanocatalytic therapy for obesity and associated diseases
Zheng, L., Than, A., Zan, P., Li, D., Zhang, Z., Leow, M. K., & Chen, P. (2024) · Theranostics · doi:10.7150/thno.99948 · Cited by 18
“…including oxidative stress, chronic inflammation, hypoxia, over-release of free fatty acids and proinflammatory factors, and altered secretion of adipokines, which increase the risk of developing various critical diseases, such as type 2 diabetes, cardiovascular diseases, and some cancers [5-7].”
BackgroundBaş, D., Arıbal, E., Vardareli, E., Sönmez, Ö., Uluç, B. O., Özden, B. Ç., & Sonkaya, A. (2022) · Nutrition in Clinical Practice · doi:10.1002/ncp.10947 · Cited by 19
Lysosomal cathepsins act in concert with Gasdermin-D during NAIP/NLRC4-dependent IL-1β secretion
Branco, L. M., Amaral, M. P., Boekhoff, H., de Lima, A. B. F., de Farias, I. S., Lage, S. L., Pereira, G. J. S., Franklin, B. S., & Bortoluci, K. R. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05476-3 · Cited by 18
Ning, Y., Lin, K., Fang, J., Chen, X., Hu, X., Liu, L., Zhao, Q., Wang, H., & Wang, F. (2023) · Journal of Immunology Research · doi:10.1155/2023/7040113 · Cited by 17
“Recent studies demonstrated that inflammasome promote tumor progression in skin and breast cancer [54, 55].”
BackgroundPyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications
Cao, Q., Zhang, J., Sun, D.-Y., Fu, J., Wu, W., Chen, X., Li, D., & Wang, P. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0257 · Cited by 18
“In addition, obesity-related activation of the IL-1a signaling pathway by the NLRC4 inflammasome promotes breast cancer progression, indicating that obesity enables breast cancer progression (Kolb et al., 2016).”
The Role of Inflammasome-Associated Innate Immune Receptors in Cancer
Dawson, R., & Jenkins, B. J. (2024) · Immune Network · doi:10.4110/in.2024.24.e38 · Cited by 16
“By contrast, the coupling of Nlrc4 −/− mice with syngeneic orthotopic transplant models for high-fat diet-induced primary breast cancer and CRC liver metastasis revealed that NLRC4 deficiency impaired the progression of tumours (109,110).”
BackgroundYu, H. Y., Shin, J. H., Yun, H., Ryu, C., Lee, S., Heo, J., Lim, J., Park, J., Hong, K., Chung, H., et al. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10204-z · Cited by 15
Tumor Metabolism Is Affected by Obesity in Preclinical Models of Triple-Negative Breast Cancer
Yelek, C., Mignion, L., Paquot, A., Bouzin, C., Corbet, C., Muccioli, G. G., Cani, P. D., & Jordan, B. F. (2022) · Cancers · doi:10.3390/cancers14030562 · Cited by 15
“The two models, E0771 and PY8119 cells lines, have been described as sensitive to obesity-driven tumor growth [23,34].”
Nishioka, N., Naito, T., Miyawaki, T., Yabe, M., Doshita, K., Kodama, H., Miyawaki, E., Iida, Y., Mamesaya, N., Kobayashi, H., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14421 · Cited by 14
“IL-1β-induced MDSCs are activated by adipose tissues,(26) and inflammatory IL-1β is reportedly activated in the tumor microenvironment of obese breast cancer model mice.(27) Another report indicated that the total frequency of MDSCs in tumors increased significantly in kidney cancer mouse models with food-induced obes…”
BackgroundInflammasome protein scaffolds the DNA damage complex during tumor development
Shen, C. X., Pandey, A., Tuipulotu, D. E., Mathur, A., Liu, L., Yang, H., Adikari, N. K., Ngo, C., Jing, W., Feng, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01988-6 · Cited by 13
Chiu, C., Chang, H., Huang, C.-Y., Mau, C.-Z., Kuo, T., Lee, H.-C., & Huang, S. (2021) · Molecules · doi:10.3390/molecules26092482 · Cited by 13
“expression in tumor tissues, eventually favoring tumor angiogenesis [39].”
BackgroundJing, X., Yun, Y., Ji, X., Yang, E., & Li, P. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s424326 · Cited by 14
“Kolb et al reported that obesity could induce the activation of NLRC4 and IL-1β, further change the VEGFA expression, and finally promote progression of breast cancer.(32) In addition, Koichiro et al observed that NLRC4 could drive M2 polarization of tumorassociated macrophages and upregulate IL-1β and VEGF levels, re…”
BackgroundBustamante-Marin, X. M., Merlino, J. L., Devericks, E. N., Carson, M. S., Hursting, S. D., & Stewart, D. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.632284 · Cited by 12
Herrero‐Aguayo, V., Sáez-Martínez, P., Lopez-Canovas, J. L., Prados-Carmona, J. J., Alcantara-Laguna, M. D., L‐López, F., Molina-Puerta, M. J., Calañas-Continente, A., Membrives, A., Castilla, J., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab586 · Cited by 12
Dai, J., Yang, C., Shueng, P., Wang, Y., Huang, C.-S., Chao, Y., Chen, C., & Lin, C. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30985 · Cited by 12
“…obesity increases tumor‐ infiltrating myeloid cells which elevates the expression of interleukin‐1β (IL‐1β), that drives breast cancer progression (Kolb et al., 2016), and obesity‐induced inflammation also alters the composition of tumors, creating a microenvironment conducive to…”
BackgroundInflammasomes in breast cancer: the ignition spark of progression and resistance?
Elgohary, S., & Tayebi, H. M. E. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.14 · Cited by 14
Castillo, D. R., Jeon, W. J., Park, D., Pham, B., Yang, C., Joung, B., Moon, J. H., Lee, J., Chong, E. G., Park, K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411547 · Cited by 11
Bianchi, F., Roccabianca, P., Vianello, E., Gentile, G., Sala, L. L., Bandera, F., Tacchini, L., Zoia, R., Romanelli, M. M. C., & Dozio, E. (2025) · Biomolecules · doi:10.3390/biom15030333 · Cited by 11
“Given that HF diet and NLRC4 affect gut permeability and microbiota homeostasis, therefore contributing to endotoxemia and endotoxemia-related inflammation [47,48], the investigation of NLRC4 activation in obesity appears to be intriguing as well, but few data are available right now [49,50].”
Chi, P., Wu, K.-T., Chen, P., Chen, C. O., Su, Y., Yang, C., & Chen, J. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.939857 · Cited by 13
Nguyen, T.-K., Kumar, R. P., & Park, P. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01437-2 · Cited by 11
Mechanism of inflammasomes in cancer and targeted therapies
Gu, Q., Zou, J., Zhou, Y. Y., & Deng, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1133013 · Cited by 12
Davari, F., Shokri‐Shirvani, J., Sepidarkish, M., & Nouri, H. R. (2023) · Apmis · doi:10.1111/apm.13323 · Cited by 11
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes
Paudel, B. B., Tan, S., Fox, T. E., Ung, J., Golla, U., Shaw, J. J. P., Dunton, W., Lee, I., Fares, W. A., Patel, S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010535 · Cited by 11
Li, F., Gao, T., Li, Z., Dou, H., Ba, Y., Jia, S., Luo, D., & Xiao, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102292 · Cited by 10
“It has been established that the activation of inflammatory pathways linked to obesity and IR promotes the advance of breast cancer, highlighting the significance of regulating insulin sensitivity as a prospective preventive strategy [19].”
Hu, J., Tian, C., Zhao, Y., Guo, Y., & Chen, S. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02697-w · Cited by 10
“The obesity-triggered NLRC4 inflammasome was found to be activated in tumor-infiltrating myeloid cells [25].”
BackgroundZhang, H., Yu, X., Yang, J., He, G., Zhang, X., Wu, X., Li, S., Zhou, Y., Cheng, X., Liu, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933779 · Cited by 10
Fernandes, F. P., Cambui, R. A. G., Soares, J. L. D. S., dos Reis, E. C., Leal, V. N. C., & Pontillo, A. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03241-2 · Cited by 11
“The activation of the inflammasome was associated with neoplastic transformation in melanoma [5] and breast cancer [6].”
BackgroundThe NLRC4 inflammasome: The pieces of the puzzle are falling into place
Hafner‐Bratkovič, I. (2017) · Inflammasome · doi:10.1515/infl-2017-0002 · Cited by 11
Subgingival microbial profile of women with breast cancer: a cross-sectional study
Bernhard, V. R., Faveri, M., Santos, M. S., Gomes, M. D. C. M., Batitucci, R. G., Tanaka, C. J., Feres, M., & Feitosa, A. C. R. (2019) · Applied cancer research/Applied Cancer Research · doi:10.1186/s41241-019-0082-3 · Cited by 10
Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study
Murto, M. O., Artama, M., Pukkala, E., Visvanathan, K., & Murtola, T. J. (2018) · International Journal of Cancer · doi:10.1002/ijc.31250 · Cited by 10
Amaral, M. P., Cardoso, F. D., de Farias, I. S., de Souza, R. Q., Matteucci, K. C., Torrecilhas, A. C., & Bortoluci, K. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1282856 · Cited by 9
Zhou, Z., Xu, J., Huang, N., Tang, J., Ma, P., & Cheng, Y. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s353762 · Cited by 8
Ageing, Metabolic Dysfunction, and the Therapeutic Role of Antioxidants
Santos, A. L., & Sinha, S. (2023) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-26576-1_15 · Cited by 8
MS-CASPT2 studies on the mechanistic photophysics of tellurium-substituted guanine and cytosine
Zhu, Y.-H., Zhang, T., Tang, X.-F., Xie, B., & Cui, G. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp01142a · Cited by 8
Zhang, Z., li, X., Lu, T., Yang, J., Han, X., Bi, Z., Luo, J., Alu, A., Hong, W., Chen, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69546-2 · Cited by 7
Complex Interplay Between Obesity and BRCA1/2‐Associated Breast Cancer: An Overview
Giordano, C., Puzzo, M., Malivindi, R., Cristofaro, D., Gelsomino, L., Bonofiglio, D., Capalbo, C., Andò, S., Barone, I., & Catalano, S. (2025) · Obesity Reviews · doi:10.1111/obr.13969 · Cited by 7
Gibson, J. T., Norris, K. E., Wald, G., Rosean, C. M. B., Thomas, L. J., Boi, S. K., Bertrand, L. A., Bing, M. T., Gordetsky, J., Deshane, J. S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233795 · Cited by 7
Xiong, M., Xie, S., Cai, C., Ma, J., Yang, J., Gu, Y., Ni, J., Cui, H., & Sha, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-02753-3 · Cited by 6
“NLRC4 promotes breast cancer progression by producing the pro-inflammatory cytokine interleukin (IL)-1β [23] and plays a key role in the growth and recurrence of liver metastases in the context of non-alcoholic fatty liver disease (NAFLD) and colorectal cancer [24].”
Turbitt, W. J., Boi, S. K., Gibson, J. T., Orlandella, R. M., & Norian, L. A. (2021) · Cancers · doi:10.3390/cancers13102295 · Cited by 6
Dong, Y. W., Yi, L., Song, Q., & Yao, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.997319 · Cited by 6
Matter of Fat: Cancer‐Associated Adipocytes as Mediators of Tumor Progression and Immune Evasion
Sureka, N., Chohan, S., Zaheer, S., Aden, D., Ahuja, S., Agravat, A. H., Goel, S., Hassan, M. J., Chawgthu, L., Nobin, H., et al. (2025) · Cell Biology International · doi:10.1002/cbin.70085 · Cited by 5
“A production within the TME, facilitating endothelial tube formation and thereby driving tumor angiogenesis and BC metastasis (Kolb et al. 2016).”
In silico pathway analysis based on chromosomal instability in breast cancer patients
Kour, A., Sambyal, V., Guleria, K., Singh, N. R., Uppal, M. S., Manjari, M., & Sudan, M. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00811-z · Cited by 6
“In the context of obesity, the tumor microenvironment induces an enhanced level of tumor-in ltrating myeloid cells with an activated NLRC4 in ammasome which further activates IL-1b, thus driving progression of disease through adipocyte-mediated VEGFA expression and angiogenesis [100].”
BackgroundInflammasome-Independent Roles of NLR and ALR Family Members
Gupta, S., Cassel, S. L., & Sutterwala, F. S. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3350-2_2 · Cited by 5
Self-citationObesity Does Not Exacerbate the Protumorigenic Systemic Environment in Sarcoma Subjects
Buchta, C. M., Boi, S. K., Miller, B. J., Milhem, M. M., & Norian, L. A. (2017) · ImmunoHorizons · doi:10.4049/immunohorizons.1700001 · Cited by 4
Impact of anesthesia on postoperative breast cancer prognosis: A narrative review
Tang, Y., Guo, S., Chen, Y., Liu, L., Liu, M., He, R., & Wu, Q. (2023) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2023.01065 · Cited by 4
Unraveling the Link Between Obesity and Keratoconus Risk Based on Genetic Evidence
Huang, Y., Zhuang, J., Liu, C. X., Liu, S., Ren, H., Zhang, Q., Yan, L., Qiu, J. F., Yu, N., Yu, K., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.5.20 · Cited by 4
“7,8 Previous research has explored the relationship between obesity and keratoconus; however, notable discrepancies persist within the literature.”
Kuriakose, B. B., Zwamel, A. H., Mutar, A. A., Uthirapathy, S., Bishoyi, A. K., Naidu, K. S., Hjazi, A. M., Nakash, P., Arya, R., & Almalki, S. G. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152337 · Cited by 4
Liu, S., & Zhang, J. (2025) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.70035 · Cited by 5
“94 In pancreatic adenocarcinoma, inhibiting NLRP3, ASC, and caspase - 1 was shown to reduce cell growth and metastasis.”
Gut Microbiota and Cancer Correlates
Malaviya, A., Paari, K. A., Malviya, S., Kondapalli, V. K., Ghosh, A., & Samuel, R. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8214-1_1 · Cited by 5
Vastrad, B. M., Pattanashetti, S., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-7522725/v1 · Cited by 5
Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies
Ouyang, D., Chen, R., Xie, H., Yang, X., Li, Q., & Chen, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.007 · Cited by 3
Ultrasound Responsive Nanotherapeutics for Multimodal Reprogramming of Obese Fat
Zheng, L., Leoi, M. W. N., Than, A., Leow, M. K., Shabbir, A., Li, D., & Chen, P. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00047 · Cited by 3
Parsa, S., Sarkani, E. O., Chaleshtori, Z. M., Darash, S., Fotros, N., Iraj, K. M., Ehsani, F. Z., Naeini, Y. M., Yahyazadeh, S., Fatehpour, M., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116454 · Cited by 3
Zhang, Z., Li, Y., Lv, Z., & Man, S. M. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169829 · Cited by 3
Lactic acid induces dendritic cell pyroptosis through MCT-1 to promote tumor immune evasion
Yang, S., Lin, L., Zheng, X., Li, J., Qin, R., Wu, Y., & Xu, J. (2026) · Oncogene · doi:10.1038/s41388-026-03825-6 · Cited by 3
Metadata
- Authors
- Kolb, R., Phan, L., Borcherding, N., Liu, Y., Yuan, F., Janowski, A. M., Xie, Q., Markan, K. R., Li, W., Potthoff, M. J., Fuentes-Mattei, E., Ellies, L. G., Knudson, C. M., Lee, M.-H., Yeung, S.-C. J., Cassel, S. L., Sutterwala, F. S., & Zhang, W.
- Affiliations
- University of Iowa (US)
- The University of Texas MD Anderson Cancer Center (US)
- Central South University (CN)
- University of California San Diego (US)
- Corresponding author
- Zhang, Weizhou
- ORCID
- Venue
- Nature Communications
- Published
- 2016-10-06
- Volume
- 7
- Issue
- 1
- Pages
- 13007-13007
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5059727
- OpenAlex
- W2529393815
- Cited by
- 239
- References
- 58
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 17 · 2023: 34 · 2022: 27 · 2021: 37 · 2020: 39 · 2019: 24 · 2018: 17 · 2017: 14 · 2016: 2
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (NIH T32, KG081048, NIH-R01, AI118719, CA158055)
- University of Texas Health Science Center at San Antonio
- Holden Comprehensive Cancer Center, University of Iowa (P30-CA086862)
- National Cancer Institute (K99CA158055, CA203834, R00CA158055, R01CA200673, CA200673, L30 CA199587, R01CA203834, K22CA118182, P30CA086862)
- National Institute of Allergy and Infectious Diseases (R56AI118719, T32AI007260, R01AI104706, T32AI007485, T32AI007517)
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK111758)
- National Institute on Minority Health and Health Disparities (L60 MD006355)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- obesity, breast cancer progression, NLRC4 inflammasome, tumor microenvironment, VEGF-A, angiogenesis, adipocytes, metformin
- MeSH terms
- Animals, Breast, Breast Neoplasms, Calcium-Binding Proteins, Female, Humans, Mammary Neoplasms, Experimental, Mice, Inbred C57BL, Neoplasm Transplantation, Obesity, Signal Transduction, Lymphocytes, Tumor-Infiltrating, Disease Progression, Myeloid Cells, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice, CARD Signaling Adaptor Proteins, Interleukin-1beta, Inflammasomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.